Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4MS | ISIN: BMG762791017 | Ticker-Symbol: 87S
Frankfurt
06.06.25 | 15:29
9,664 Euro
+0,67 % +0,064
1-Jahres-Chart
ROIVANT SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
ROIVANT SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
9,7409,98006.06.
9,7489,95206.06.

Aktuelle News zur ROIVANT SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline2
29.05.Roivant Sciences: EPS verfehlt Schätzungen um 0,03 $ - Umsatz schlechter als erwartet5
29.05.Roivant Sciences Ltd. - 10-K, Annual Report2
29.05.Roivant Sciences Ltd. - 8-K, Current Report1
ROIVANT SCIENCES Aktie jetzt für 0€ handeln
29.05.Roivant Sciences GAAP EPS of -$0.29 misses by $0.07, revenue of $7.57M2
29.05.Roivant Sciences: Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update107BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025...
► Artikel lesen
28.05.Roivant Sciences' Earnings Outlook2
28.05.H.C. Wainwright maintains $18 target on Roivant Sciences stock1
15.05.Roivant Sciences: Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 20251
02.05.Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential1
22.04.Roivant Sciences stock holds $18 target, management shuffle3
21.04.Cantor Fitzgerald maintains overweight on Roivant Sciences stock1
21.04.Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift4
21.04.Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts1
21.04.Roivant Sciences Ltd. - 8-K, Current Report1
21.04.Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402266Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO...
► Artikel lesen
21.04.Roivant Sciences: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-14021
10.04.Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In2
19.03.Roivant, Immunovant Succeed In Phase 3. But There's A Twist - And Shares Tumbled.7
19.03.Roivant: Immunovant Reports Positive Results From MG And CIDP Studies; Stocks Down In Pre-market2
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1